Sphere-9 Catheter and Affera Ablation System
Medtronic, Inc. · Decision date Oct 24, 2024
What did the FDA approve?
FDA records P240013 as an original PMA application. The recorded decision is approval, dated Oct 24, 2024.
FDA approval order statement
approval for the Sphere-9 Catheter and Affera Ablation System. This device is indicated for use in cardiac electrophysiological mapping (stimulation and electrogram recording) and for treatment of drug refractory, recurrent, symptomatic persistent atrial fibrillation (episode duration less than 1 year) and radiofrequency ablation of cavotricuspid isthmus dependent atrial flutter when used with the Affera mapping system.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 24, 2024
Regulatory record facts
- Identifier
- P240013
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Oct 24, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240013 received
Application receipt date recorded by FDA.
P240013 · FDA decision
APPR
P240013/S031 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S028 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S032 · Related supplement
Affera Sphere-9 Mapping and Ablation Catheter
Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Sphere-9 Catheter and Affera Ablation SystemP240013/S031 | Medtronic, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Sphere-9 Catheter and Affera Ablation SystemP240013/S028 | Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P240013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
